{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:49:11Z","timestamp":1789084151514,"version":"build-2803163510"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32HL116275"],"award-info":[{"award-number":["T32HL116275"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009429","name":"Israel National Road Safety Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine and Research"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.resmer.2025.101170","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T21:25:02Z","timestamp":1743801902000},"page":"101170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Progressive course of anti-nuclear matrix protein-2 (NXP-2) positive-interstitial lung disease"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6186-5732","authenticated-orcid":false,"given":"Bess M.","family":"Flashner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3215-4808","authenticated-orcid":false,"given":"Andrew J.","family":"Synn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia K.","family":"Munchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6190-624X","authenticated-orcid":false,"given":"Lida P.","family":"Hariri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona K.","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney B.","family":"Montesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry S.","family":"Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2538-391X","authenticated-orcid":false,"given":"Mary B.","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6054-3558","authenticated-orcid":false,"given":"Rene S.","family":"Bermea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Hallowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resmer.2025.101170_bib0001","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resmer.2025.101170_bib0002","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an Update) and progressive Pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resmer.2025.101170_bib0003","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s13317-014-0060-4","article-title":"Myositis autoantibodies and clinical phenotypes","volume":"5","author":"Ghirardello","year":"2014","journal-title":"Autoimmun Highlights"},{"key":"10.1016\/j.resmer.2025.101170_bib0004","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.chest.2023.01.031","article-title":"Diagnosis and management of myositis-associated lung disease","volume":"163","author":"Hallowell","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.resmer.2025.101170_bib0005","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2018-215004","article-title":"Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis","volume":"78","author":"Sabbagh","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resmer.2025.101170_bib0006","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-019-1231-7","article-title":"Presentations and outcomes of interstitial lung disease and the anti-Ro52 autoantibody","volume":"20","author":"Sclafani","year":"2019","journal-title":"Respir Res"},{"key":"10.1016\/j.resmer.2025.101170_bib0007","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1093\/rheumatology\/keab166","article-title":"A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies","volume":"60","author":"Oldroyd","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.resmer.2025.101170_bib0008","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.autrev.2018.10.004","article-title":"Autoantibodies in idiopathic inflammatory myopathies: clinical associations and laboratory evaluation by mono- and multispecific immunoassays","volume":"18","author":"Damoiseaux","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.resmer.2025.101170_bib0009","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.autrev.2018.10.004","article-title":"Autoantibodies in idiopathic inflammatory myopathies: clinical associations and laboratory evaluation by mono- and multispecific immunoassays","volume":"18","author":"Damoiseaux","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.resmer.2025.101170_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.resmer.2025.101170_bib0011","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1111\/1756-185X.14799","article-title":"Beyond skin and muscle: the unexplored territory of interstitial lung disease in anti-NXP2-positive myositis","volume":"26","author":"Liu","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.resmer.2025.101170_bib0012","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/cen3.12419","article-title":"Diagnosis of dermatomyositis: autoantibody profile and muscle pathology","volume":"8","author":"Uruha","year":"2017","journal-title":"Clin Exp Neuroimmunol"},{"key":"10.1016\/j.resmer.2025.101170_bib0013","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/25785826.2018.1531188","article-title":"Clinical significance of myositis-specific autoantibodies","volume":"41","author":"Nakashima","year":"2018","journal-title":"Immunol Med"},{"key":"10.1016\/j.resmer.2025.101170_bib0014","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/1744666X.2019.1699059","article-title":"Current understanding and recent advances in myositis-specific and -associated autoantibodies detected in patients with dermatomyositis","volume":"16","author":"Gono","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.resmer.2025.101170_bib0015","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/BOR.0000000000000329","article-title":"Recent advances in dermatomyositis-specific autoantibodies","volume":"28","author":"Fujimoto","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.resmer.2025.101170_bib0016","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00408-018-0108-8","article-title":"Prevalence of myositis-specific antibodies in idiopathic interstitial pneumonias","volume":"196","author":"de Sadeleer","year":"2018","journal-title":"Lung"},{"key":"10.1016\/j.resmer.2025.101170_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2013-eular.1516","article-title":"First report of anti-MDA5 antibodies in a cohort of Italian patients with dermatomyositis: clinical and serologic correlations","volume":"72","author":"Ceribelli","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resmer.2025.101170_bib0018","article-title":"Association between clinical phenotypes of dermatomyositis and polymyositis with myositisspecific antibodies and overlap systemic autoimmune diseases","volume":"100","author":"Chiang","year":"2021","journal-title":"Medicine (United States)"},{"key":"10.1016\/j.resmer.2025.101170_bib0019","article-title":"Amyopathic dermatomyositis and interstitial lung disease associated with anti-NXP2 autoantibody","volume":"195","author":"Reed","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resmer.2025.101170_bib0020","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12890-018-0609-5","article-title":"Elevated \u03b1-defensin levels in plasma and bronchoalveolar lavage fluid from patients with myositis-associated interstitial lung disease","volume":"18","author":"Sakamoto","year":"2018","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.resmer.2025.101170_bib0021","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jns.2018.12.040","article-title":"Myositis-specific autoantibodies in dermatomyositis\/polymyositis with interstitial lung disease","volume":"397","author":"Li","year":"2019","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.resmer.2025.101170_bib0022","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1183\/16000617.00006714","article-title":"Interstitial lung disease in an adult patient with dermatomyositis and anti-NXP2 autoantibody","volume":"24","author":"Gossez","year":"2015","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.resmer.2025.101170_bib0023","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/annrheumdis-2020-eular.1384","article-title":"Anti-NXP2 antibodies: clinical and serological associations in a multicentric Italian study","volume":"79","author":"Fredi","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resmer.2025.101170_bib0024","first-page":"805","article-title":"Myositis-pecific autoantibodies and clinical phenotypes correlate with the aberrant expression of immune-related microRNAs in dermatomyositis","volume":"49","author":"Ye","year":"2019","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.resmer.2025.101170_bib0025","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1080\/17476348.2020.1767598","article-title":"Lung involvement associated with anti-NXP2 autoantibodies in inflammatory myopathies: a French monocenter series","volume":"14","author":"Bermudez","year":"2020","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.resmer.2025.101170_bib0026","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.chest.2019.05.023","article-title":"Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease","volume":"156","author":"Huapaya","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.resmer.2025.101170_bib0027","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/annrheumdis-2019-eular.7758","article-title":"Sequence of clinical symptoms onset and its correlation to the autoantibodies presence in patients with idiopathic inflammatory myopathies","volume":"78","author":"Szczesny","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resmer.2025.101170_bib0028","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1136\/annrheumdis-2020-eular.6437","article-title":"Emerging autoantibodies panel (myositis associated and myositis specific antibodies) in inflammatory myopathies: the frequencies of and relationship with clinical features","volume":"79","author":"Yardimci","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resmer.2025.101170_bib0029","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1007\/s00330-019-06152-5","article-title":"Prognostic factors of interstitial lung disease progression at sequential HRCT in anti-synthetase syndrome","volume":"29","author":"Liu","year":"2019","journal-title":"Eur Radiol"},{"key":"10.1016\/j.resmer.2025.101170_bib0030","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1007\/s10067-021-05667-x","article-title":"Association of anti-NXP2 antibody with clinical characteristics and outcomes in adult dermatomyositis: results from clinical applications based on a myositis-specific antibody","volume":"40","author":"Yan","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.resmer.2025.101170_bib0031","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1007\/s10067-018-4216-x","article-title":"Calcinosis and malignancy are rare in Chinese adult patients with myositis and nuclear matrix protein 2 antibodies identified by an unlabeled immunoprecipitation assay","volume":"37","author":"Wang","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.resmer.2025.101170_bib0032","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/art.40491","article-title":"Differential clinical associations of anti-nuclear Matrix protein 2 autoantibodies in patients with idiopathic inflammatory myopathies","volume":"70","author":"Yang","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.resmer.2025.101170_bib0033","doi-asserted-by":"crossref","DOI":"10.1002\/acr.23188","article-title":"Dermatomyositis patients with anti-nuclear matrix protein-2 autoantibodies have more edema, more severe muscle disease, and increased malignancy risk","volume":"69","author":"Albayda","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.resmer.2025.101170_bib0034","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/acr.23210","article-title":"Cutaneous and systemic findings associated with nuclear matrix protein 2 antibodies in adult dermatomyositis patients","volume":"69","author":"Rogers","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.resmer.2025.101170_bib0035","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/s12890-021-01737-7","article-title":"Interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies","volume":"21","author":"Misra","year":"2021","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.resmer.2025.101170_bib0036","unstructured":"Myositis specific 11 antibody panel | test detail | Quest diagnostics n.d. https:\/\/testdirectory.questdiagnostics.com\/test\/test-detail\/94777\/myositis-specific-11-antibodies-panel?cc=MASTER (accessed June 24, 2024)."},{"key":"10.1016\/j.resmer.2025.101170_bib0037","unstructured":"FMYO3 - Overview: myoMarker 3 profile n.d. https:\/\/www.mayocliniclabs.com\/test-catalog\/Overview\/75595 (accessed June 24, 2024)."},{"key":"10.1016\/j.resmer.2025.101170_bib0038","first-page":"277","article-title":"American Thoracic Society\/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial pneumonias","volume":"165","author":"Travis","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resmer.2025.101170_bib0039","doi-asserted-by":"crossref","first-page":"E36","DOI":"10.1164\/rccm.202005-2032ST","article-title":"Diagnosis of hypersensitivity pneumonitis in adults: an official ATS\/JRS\/ALAT clinical practice guideline","volume":"202","author":"Raghu","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resmer.2025.101170_bib0040","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an Update) and progressive Pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resmer.2025.101170_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103335","article-title":"The prevalence and effects of treatments of rapidly progressive interstitial lung disease of dermatomyositis\/polymyositis adults: a systematic review and meta-analysis","volume":"22","author":"Wang","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.resmer.2025.101170_bib0042","article-title":"Acute exacerbation in interstitial lung disease","volume":"4","author":"Leuschner","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.resmer.2025.101170_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.chstcc.2023.100020","article-title":"ICU management of the patient with fibrotic interstitial lung disease","volume":"1","author":"Krishnan","year":"2023","journal-title":"CHEST Critical Care"},{"key":"10.1016\/j.resmer.2025.101170_bib0044","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis. An International Working Group Report","volume":"194","author":"Collard","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resmer.2025.101170_bib0045","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s10067-020-05291-1","article-title":"Assessment of diagnostic utility, clinical phenotypic associations, and prognostic significance of anti-NXP2 autoantibody in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis","volume":"40","author":"Li","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.resmer.2025.101170_bib0046","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/jdv.14759","article-title":"Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients","volume":"32","author":"Best","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.resmer.2025.101170_bib0047","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.resmer.2025.101170_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.151998","article-title":"Myositis-specific autoantibodies in clinical practice: improving the performance of the immunodot","volume":"55","author":"Bories","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.resmer.2025.101170_bib0049","doi-asserted-by":"crossref","first-page":"A49","DOI":"10.1136\/annrheumdis-2011-201235.17","article-title":"Anti-MJ\/NXP-2 antibodies are the most common specifcity in a cohort of adult caucasian patients with dermatomyositis","volume":"71","author":"Ceribelli","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resmer.2025.101170_bib0050","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1136\/annrheumdis-2019-eular.5828","article-title":"The spectrum of myositis antibodies: clinical correlation and prevalence of anti-DFS70","volume":"78","author":"Esposito","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resmer.2025.101170_bib0051","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2011-200697","article-title":"Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy","volume":"71","author":"Ichimura","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resmer.2025.101170_bib0052","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/rheumatology\/kes033","article-title":"Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2","volume":"51","author":"Ishikawa","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.resmer.2025.101170_bib0053","first-page":"46","article-title":"Presence of myositis-associated antibodies, especially SSA52, predicts more severe lung involvement: a study of 70 patients with inflammatory myopathies","volume":"50","author":"Marklund","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.resmer.2025.101170_bib0054","doi-asserted-by":"crossref","unstructured":"Seishima M., Ito M., Moriya C., Matsuyama K., Shu E., Hamaguchi Y. Single case A case of dermatomyositis coexisting with both Anti-Mi-2 and Anti-NXP-2 antibodies 2020. https:\/\/doi.org\/10.1159\/000507504.","DOI":"10.1159\/000507504"},{"key":"10.1016\/j.resmer.2025.101170_bib0055","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01205-2020","article-title":"Myositis-specific antibodies identify a distinct interstitial pneumonia with autoimmune features phenotype","volume":"56","author":"Graham","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resmer.2025.101170_bib0056","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.resmer.2025.101170_bib0057","doi-asserted-by":"crossref","first-page":"R78","DOI":"10.1186\/ar2276","article-title":"Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes","volume":"9","author":"Koenig","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.resmer.2025.101170_bib0058","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12890-020-01256-x","article-title":"Double anti-PL-7 and anti-MDA-5 positive amyopathic dermatomyositis with rapidly progressive interstitial lung disease in a Hispanic patient","volume":"20","author":"Li","year":"2020","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.resmer.2025.101170_bib0059","doi-asserted-by":"crossref","unstructured":"Pellegrino R., Viegi G., Brusasco V., Crapo R.O., Burgos F., Casaburi R., et al. Interpretative strategies for lung function tests n.d. https:\/\/doi.org\/10.1183\/09031936.05.00035205.","DOI":"10.1183\/09031936.05.00035205"}],"container-title":["Respiratory Medicine and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041225000170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041225000170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T20:23:50Z","timestamp":1762633430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590041225000170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":59,"alternative-id":["S2590041225000170"],"URL":"https:\/\/doi.org\/10.1016\/j.resmer.2025.101170","relation":{},"ISSN":["2590-0412"],"issn-type":[{"value":"2590-0412","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progressive course of anti-nuclear matrix protein-2 (NXP-2) positive-interstitial lung disease","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine and Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resmer.2025.101170","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"101170"}}